A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies von Rasco, Drew W, Papadopoulos, Kyriakos P, Pourdehnad, Michael, Gandhi, Anita K, Hagner, Patrick R, Li, Yan, Wei, Xin, Chopra, Rajesh, Hege, Kristen, DiMartino, Jorge, Shih, Kent

Volltext

CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL von Hagner, Patrick R., Man, Hon-Wah, Fontanillo, Celia, Wang, Maria, Couto, Suzana, Breider, Mike, Bjorklund, Chad, Havens, Courtney G., Lu, Gang, Rychak, Emily, Raymon, Heather, Narla, Rama Krishna, Barnes, Leo, Khambatta, Gody, Chiu, Hsiling, Kosek, Jolanta, Kang, Jian, Amantangelo, Michael D., Waldman, Michelle, Lopez-Girona, Antonia, Cai, Ti, Pourdehnad, Michael, Trotter, Matthew, Daniel, Thomas O., Schafer, Peter H., Klippel, Anke, Thakurta, Anjan, Chopra, Rajesh, Gandhi, Anita K.

Volltext

Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy von Ioannou, Nikolaos, Hagner, Patrick R., Stokes, Matt, Gandhi, Anita K., Apollonio, Benedetta, Fanous, Mariam, Papazoglou, Despoina, Sutton, Lesley-Ann, Rosenquist, Richard, Amini, Rose-Marie, Chiu, Hsiling, Lopez-Girona, Antonia, Janardhanan, Preethi, Awan, Farrukh T., Jones, Jeffrey, Kay, Neil E., Shanafelt, Tait D., Tallman, Martin S., Stamatopoulos, Kostas, Patten, Piers E.M., Vardi, Anna, Ramsay, Alan G.

Volltext

Hypoxia-inducible Factor-1α (HIF-1α) Promotes Cap-dependent Translation of Selective mRNAs through Up-regulating Initiation Factor eIF4E1 in Breast Cancer Cells under Hypoxia Condi... von Yi, Tingfang, Papadopoulos, Evangelos, Hagner, Patrick R., Wagner, Gerhard

Volltext

Targeting the translational machinery as a novel treatment strategy for hematologic malignancies von Hagner, Patrick R., Schneider, Abraham, Gartenhaus, Ronald B.

Volltext

Phase I, multicenter, dose‐escalation study of avadomide in adult Japanese patients with advanced malignancies von Hatake, Kiyohiko, Chou, Takaaki, Doi, Toshihiko, Terui, Yasuhito, Kato, Harumi, Hirose, Takayuki, Seo, Sachiko, Pourdehnad, Michael, Ogaki, Yumi, Fujimoto, Hiroshi, Hagner, Patrick R., Yamamoto, Kazuhito

Volltext

Extended exposure to low doses of azacitidine induces differentiation of leukemic stem cells through activation of myeloperoxidase von Jeyaraju, Danny V, Alapa, Maryam, Polonskaia, Ann, Risueño, Alberto, Subramanyam, Prakash, Anand, Amit, Ghosh, Kaushik, Kyriakopoulos, Charalampos, Hemerich, Daiane, Hurren, Rose, Wang, Xiaoming, Gronda, Marcela, Ahsan, Aarif, Chiu, Hsiling, Thomas, Geethu, Lind, Evan F, Menezes, Daniel L, Schimmer, Aaron D, Hagner, Patrick R, Gandhi, Anita, Thakurta, Anjan G

Volltext

Interactome of Aiolos/Ikaros Reveals Combination Rationale of Cereblon Modulators with HDAC Inhibitors in DLBCL von Hagner, Patrick R, Chiu, Hsiling, Chopra, Vivek S, Colombo, Martino, Patel, Nisha, Estevez, Maria Ortiz, Waldman, Michelle F, Loos, Remco, Towfic, Fadi, Gandhi, Anita K

Volltext

Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier von Carpio, Cecilia, Bouabdallah, Reda, Ysebaert, Loïc, Sancho, Juan-Manuel, Salles, Gilles, Cordoba, Raul, Pinto, Antonio, Gharibo, Mecide, Rasco, Drew, Panizo, Carlos, Lopez-Martin, Jose A., Santoro, Armando, Salar, Antonio, Damian, Silvia, Martin, Alejandro, Verhoef, Gregor, Van den Neste, Eric, Wang, Maria, Couto, Suzana, Carrancio, Soraya, Weng, Andrew, Wang, Xuehai, Schmitz, Frank, Wei, Xin, Hege, Kristen, Trotter, Matthew W.B., Risueño, Alberto, Buchholz, Tonia J., Hagner, Patrick R., Gandhi, Anita K., Pourdehnad, Michael, Ribrag, Vincent

Volltext

Combination lenalidomide‐rituximab immunotherapy activates anti‐tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma von Chiu, Hsiling, Trisal, Preeti, Bjorklund, Chad, Carrancio, Soraya, Toraño, Estela G., Guarinos, Carla, Papazoglou, Despoina, Hagner, Patrick R., Beldi‐Ferchiou, Asma, Tarte, Karin, Delfau‐Larue, Marie‐Hélène, Morschhauser, Franck, Ramsay, Alan G., Gandhi, Anita K.

Volltext

Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell‐mediated cytotoxicity von Hagner, Patrick R., Chiu, Hsiling, Ortiz, Maria, Apollonio, Benedetta, Wang, Maria, Couto, Suzana, Waldman, Michelle F., Flynt, Erin, Ramsay, Alan G., Trotter, Matthew, Gandhi, Anita K., Chopra, Rajesh, Thakurta, Anjan

Volltext

Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1 von Wu, Wenchao, Nelson, Geoffrey M., Koch, Raphael, Donovan, Katherine A., Nowak, Radosław P., Heavican-Foral, Tayla B., Nirmal, Ajit J., Liu, Huiyun, Yang, Lei, Duffy, Jessica, Powers, Foster, Stevenson, Kristen E., Jones, Marcus Kenneth, Ng, Samuel Y., Wu, Gongwei, Jain, Salvia, Xu, Ran, Amaka, Sam, Trevisani, Christopher, Donaldson, Nicholas L., Hagner, Patrick R., de Leval, Laurence, Gaulard, Philippe, Iqbal, Javeed, Thakurta, Anjan, Fischer, Eric S., Adelman, Karen, Weinstock, David M.

Volltext

Leveraging gene expression subgroups to classify DLBCL patients and select for clinical benefit from a novel agent von Risueño, Alberto, Hagner, Patrick R., Towfic, Fadi, Fontanillo, Celia, Djebbari, Amira, Parker, Joel S., Drew, Clifton P., Nowakowski, Grzegorz S., Maurer, Matthew J., Cerhan, James R., Wei, Xin, Ren, Yan, Lee, Chung-Wein, Couto, Suzana, Wang, Maria, Pourdehnad, Michael, Gandhi, Anita K., Trotter, Matthew W.B.

Volltext

Transcriptomic classification of diffuse large B-cell lymphoma identifies a high-risk activated B-cell-like subpopulation with targetable MYC dysregulation von Stokes, Matthew E., Wenzl, Kerstin, Huang, C. Chris, Ortiz, María, Hsu, Chih-Chao, Maurer, Matthew J., Stong, Nicholas, Nakayama, Yumi, Wu, Lei, Chiu, Hsiling, Polonskaia, Ann, Danziger, Samuel A., Towfic, Fadi, Parker, Joel, King, Rebecca L., Link, Brian K., Slager, Susan L., Sarangi, Vivekananda, Asmann, Yan W., Novak, Joseph P., Sudhindra, Akshay, Ansell, Stephen M., Habermann, Thomas M., Hagner, Patrick R., Nowakowski, Grzegorz S., Cerhan, James R., Novak, Anne J., Gandhi, Anita K.

Volltext

Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study von Michot, Jean-Marie, Bouabdallah, Reda, Vitolo, Umberto, Doorduijn, Jeanette K, Salles, Gilles, Chiappella, Annalisa, Zinzani, Pier Luigi, Bijou, Fontanet, Kersten, Marie José, Sarmiento, Rafael, Mosulen, Silvia, Mendez, Cristina, Uttamsingh, Shailaja, Pourdehnad, Michael, Hege, Kristen, Chen, Tianlei, Klein, Christian, Hagner, Patrick R, Nikolova, Zariana, Ribrag, Vincent

Volltext

ATM regulates a DNA damage response posttranscriptional RNA operon in lymphocytes von Mazan-Mamczarz, Krystyna, Hagner, Patrick R., Zhang, Yongqing, Dai, Bojie, Lehrmann, Elin, Becker, Kevin G., Keene, Jack D., Gorospe, Myriam, Liu, Zhenqui, Gartenhaus, Ronald B.

Volltext

The C-Terminal Domain of Eukaryotic Initiation Factor 5 Promotes Start Codon Recognition by Its Dynamic Interplay with eIF1 and eIF2β von Luna, Rafael E., Arthanari, Haribabu, Hiraishi, Hiroyuki, Nanda, Jagpreet, Martin-Marcos, Pilar, Markus, Michelle A., Akabayov, Barak, Milbradt, Alexander G., Luna, Lunet E., Seo, Hee-Chan, Hyberts, Sven G., Fahmy, Amr, Reibarkh, Mikhail, Miles, David, Hagner, Patrick R., O'Day, Elizabeth M., Yi, Tingfang, Marintchev, Assen, Hinnebusch, Alan G., Lorsch, Jon R., Asano, Katsura, Wagner, Gerhard

Volltext

Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma von Kurata, Keiji, James-Bott, Anna, Tye, Mark A., Yamamoto, Leona, Samur, Mehmet K., Tai, Yu-Tzu, Dunford, James, Johansson, Catrine, Senbabaoglu, Filiz, Philpott, Martin, Palmer, Charlotte, Ramasamy, Karthik, Gooding, Sarah, Smilova, Mihaela, Gaeta, Giorgia, Guo, Manman, Christianson, John C., Payne, N. Connor, Singh, Kritika, Karagoz, Kubra, Stokes, Matthew E., Ortiz, Maria, Hagner, Patrick, Thakurta, Anjan, Cribbs, Adam, Mazitschek, Ralph, Hideshima, Teru, Anderson, Kenneth C., Oppermann, Udo

Volltext

Functional and molecular interactions between ERK and CHK2 in diffuse large B-cell lymphoma von Dai, Bojie, Zhao, X. Frank, Mazan-Mamczarz, Krystyna, Hagner, Patrick, Corl, Sharon, Bahassi, El Mustapha, Lu, Song, Stambrook, Peter J., Shapiro, Paul, Gartenhaus, Ronald B.

Volltext

Phase Ib study of combinations of avadomide (CC‐122), CC‐223, CC‐292, and rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma von Ribrag, Vincent, Chavez, Julio C., Boccomini, Carola, Kaplan, Jason, Chandler, Jason C., Santoro, Armando, Corradini, Paolo, Flinn, Ian W., Advani, Ranjana, Cassier, Philippe A., Sangha, Randeep, Kenkre, Vaishalee P., Isufi, Iris, Uttamsingh, Shailaja, Hagner, Patrick R., Gandhi, Anita K., Shen, Frank, Michelliza, Sophie, Haeske, Harald, Hege, Kristen, Pourdehnad, Michael, Kuruvilla, John

Volltext